HealthcareMid capRs 16,441 crRs 32.5 cr traded a dayHealthcare
Close on 2026-08-21
407.25
+2.97%
52-week range7% of the way up
385.90670.80
Market cap
16,441 cr
P/E (TTM)
57.7×
industry 44×
EPS (TTM)
7.06
Revenue YoY
-6.8%
Q1 FY27
Profit YoY
-111.9%
Net margin
-1.2%
-10.8pt vs a year ago
Growth trend
-19.8pt
vs last quarter’s YoY
1 month
+1.0%
Below 52w high
64.7%
RSI (14)
54
Daily swing
2.5%
average true range
Volume
0.5×
vs 20-day average
Traded
Rs 33 cr
median day
Close200-day averageMaterial filing
260 sessions · hover for the filing behind a move
1 week
+1.44%
1 month
+0.99%
3 months
−12.47%
6 months
−4.38%
1 year
−35.93%
The read
written from the numbers on this page
The evidence leans negative1 supporting, 6 against, 0 worth knowing
Supporting
matches near a 52-week low, which has beaten the market by +0.45 points over 20 sessions across 47,393 past signals
Against
trading 16% below its 200-day average
at 7% of its 52-week range — nearly everyone who bought in the past year is underwater
down 36% over twelve months
revenue fell 7% year on year in the quarter ending 2026-06-30
net margin has narrowed from 13.9% to -1.2% across four quarters
priced at 58× earnings against an industry median of 44× — 31% above its peers
Worth knowing
nothing the data supports either way
SYNGENE sits in Healthcare — worth checking whether the whole group is moving together or whether this name is doing it alone.
What would change this read: a close back above 483, its 200-day average.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
What is working, what is not
read from the filings, with the figure behind every line
Working3
Holds more cash than borrowings, Rs 229 cr against Rs 9 cr.
Rs 229 crRs 9 cr
Operating cash flow was Rs 915 cr against Rs 285 cr of profit over four quarters, 321% of it.
Rs 915 crRs 285 cr321%
Borrowings are 0.00 times owners' equity, Rs 9 cr against Rs 4,839 cr.
0.00Rs 9 crRs 4,839 cr
Needs watching3
Net profit -108.5% year on year, Rs 106 cr to Rs -9 cr.
-108.5%Rs 106 crRs -9 cr
Profit grew slower than revenue, -108.5% against -17.4%.
-108.5%-17.4%
Net margin moved from 11.9% to -1.2%.
11.9%-1.2%
Every figure here is computed from the company’s own filings. The wording is generated directly from the figures.
How it has performed
price return over each window, measured against zero
What the scans say today
1 of 47 matched on 2026-08-21
SYNGENE matches 1 of the 47 scans today, across 1 different kinds of evidence.
Return on capital uses profit before tax over equity plus borrowings. The textbook version adds finance costs back; those are not tagged reliably in quarterly filings, so this understates the ratio for a heavily borrowed company rather than flattering it. Balance sheets are filed half-yearly, so these can be up to six months behind the profit figures above.
Valuation against its own history
500 sessions since 2024-09-06
44×
median 53×
74×
now 58×
SYNGENE trades at 58× trailing earnings, above its median of 53× over this window — 9% more expensive than usual. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
Analyst call filings were typically +0.14pt vs the market over the next 5 sessions (n=3,352) · AGM / EGM filings were typically +0.00pt vs the market over the next 5 sessions (n=4,362) · Results filings were typically -0.52pt vs the market over the next 5 sessions (n=7,520)
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
nothing clear in the filed numbers
Going against it
revenue fell 7% against the same quarter a year earlier
profit dropped 112% year on year
net margin narrowed from 14.3% to -1.2%
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
2026-06-30 · consolidated
736
-19
-9
—
-1.2%
Q4 FY26
2026-03-31 · consolidated
1,036
196
148
3.68
14.3%
Q3 FY26
2025-12-31 · consolidated
917
28
15
0.37
1.6%
Q3 FY25
2024-12-31 · consolidated
944
181
131
3.27
13.9%
Q2 FY25
2024-09-30 · consolidated
891
137
106
2.64
11.9%
Q1 FY25
2024-06-30 · consolidated
790
101
76
1.89
9.6%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average-2.7%
Versus 200-day average-15.7%
Below 52-week high-39.3%
Above 52-week low+5.5%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)54.2
Higher closes in last 53 of 5
Six-month return−4.38%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)2.50%
Volume versus 20-day0.5x
Median daily turnoverRs 32.5 cr
Peers
Healthcare · 67 classified companies
SYNGENE trades at 57.7× trailing earnings against an industry median of 44.0× across 64 other classified companies in its industry — more expensive than them, by 31%. A multiple is a statement about expectations, not about quality: cheap usually means the market expects less, and it is often right.